University of Birmingham: Fluoropyrimidine, oxaliplatin and targeted-receptor pre-operative therapy for pateints with high-risk, operable colon cancer.
Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.
- Organisation
- University of Birmingham
- Source reference
- DARS-NIC-148379-5VSG8-v0.0
- Jurisdiction
- England
- Licence
- Open Government Licence v3.0, subject to NHS England terms and exclusions
Fluoropyrimidine, oxaliplatin and targeted-receptor pre-operative therapy for pateints with high-risk, operable colon cancer. FOxTROT is a multi-centre randomised controlled trial (RCT) with the following objectives: Primary objectives: • To determine if neoadjuvant chemotherapy±panitumumab followed by deferred surgery and completion of chemotherapy post-operatively can reduce 2-year recurrence as compared to surgery and postoperative chemotherapy±panitumumab • To determine if adding panitumumab in the neoadjuvant treatment produces a measurable increase in anti-tumour efficacy as measured by
- Register reference
- DARS-NIC-148379-5VSG8-v0.0
- Agreement period
- not published to no end date published
- For commercial purposes (as marked in the register)
- Not stated
- Release files listed by NHS England
- 17
Data approved
- MRIS - Cause of Death Report
- MRIS - Cohort Event Notification Report
Objective, as published
Fluoropyrimidine, oxaliplatin and targeted-receptor pre-operative therapy for pateints with high-risk, operable colon cancer. FOxTROT is a multi-centre randomised controlled trial (RCT) with the following objectives: Primary objectives: • To determine if neoadjuvant chemotherapy±panitumumab followed by deferred surgery and completion of chemotherapy post-operatively can reduce 2-year recurrence as compared to surgery and postoperative chemotherapy±panitumumab • To determine if adding panitumumab in the neoadjuvant treatment produces a measurable increase in anti-tumour efficacy as measured by tumour shrinkage. Secondary objectives: • To assess the accuracy of pre-treatment CT scan staging • To assess the tolerability of the neoadjuvant therapies • To assess the nature and frequency of surgical complications • To measure the impact of the treatments on participant quality of life and on resource usage
Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/https://digital.nhs.uk/binaries/content/assets/website-assets/services/dars/release-registers/releaseregister20190301_20190331.xlsx. Captured 2026-10-30.
Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.